KRYS · Krystal Biotech, Inc.
$335.19
+3.53% last session
End-of-day data · updated 2026-07-28
Market cap
$10B
Enterprise value
$10B
Trailing P/E
47.0
Forward P/E
35.6
Dividend yield
—
Beta
0.50
Avg volume
0M
Employees
0K
2D change
4.96%
5D change
7.43%
10D change
-0.86%
30D change
-5.49%
60D change
13.85%
MTD change
-5.32%
YTD change
42.70%
Analyst Outlook
Analyst estimates change daily — follow the shifts on the Estimate Trends page.
Technical Analysis
Analyst sentiment over time — KRYS
Rec Mean (blue, left — higher = more bullish) vs. price targets (right).
Investment Bank Ratings as of 2026-07-14
Latest call per bank · past 12 months
Bank of America
Buy$396
+18.1% vs priceCitigroup
Buy$378
+12.8% vs priceJefferies
Buy$371
+10.7% vs priceGoldman Sachs
Buy$327
-2.4% vs priceRecent rating actions
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-07-14 | Bank of America | Maintains | Buy | $364 → $396 |
| 2026-06-18 | TD Cowen | Maintains | Buy | $306 → $403 |
| 2026-06-16 | HC Wainwright & Co. | Maintains | Buy | $310 → $361 |
| 2026-06-01 | HC Wainwright & Co. | Reiterates | Buy | $310 |
| 2026-05-22 | HC Wainwright & Co. | Reiterates | Buy | $310 |
| 2026-05-18 | HC Wainwright & Co. | Reiterates | Buy | $310 |
| 2026-05-05 | Citigroup | Maintains | Buy | $371 → $378 |
| 2026-05-05 | Evercore ISI Group | Maintains | Outperform | $295 → $300 |
Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.
Signal Summary as of 2026-07-28
- RSI (14): RSI is 58 — neutral momentum, neither overbought nor oversold.
- Price vs 50-day MA: Trading 9.2% above the 50-day MA ($333.38).
- Price vs 200-day MA: Trading 35.6% above the 200-day MA ($268.64).
- MA cross: The 50-day MA sits above the 200-day MA (golden-cross regime) — the longer-term trend points up.
- MACD (12,26,9): MACD histogram is negative (-2.51) — short-term momentum is fading.
- 52-week range: Price is within 5% of the 52-week high ($378.15).
KRYS Price Chart
Loading chart for KRYS…
Fundamentals
About Krystal Biotech, Inc.
Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United States. The company commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). It also develops KB803 for ocular complications of dystrophic epidermolysis bullosa; KB801 for neurotrophic keratitis; KB407, which is in Phase 1 clinical trials for treating cystic fibrosis; KB111 for Hailey-Hailey disease; KB707 for solid tumors; KB304 for dynamic wrinkles; KB707 that is in Phase 1/2 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.
More in Biotechnology
VRTX
Vertex Pharmaceuticals Incorpor
$122B 5.7% YTD
REGN
Regeneron Pharmaceuticals, Inc.
$70B -13.3% YTD
ARGX
argenx SE
$56B 5.7% YTD
RVMD
Revolution Medicines, Inc.
$40B 136.1% YTD
ALNY
Alnylam Pharmaceuticals, Inc.
$37B -30.0% YTD
ONC
BeOne Medicines Ltd.
$34B 7.3% YTD
RPRX
Royalty Pharma plc
$34B 53.5% YTD
ROIV
Roivant Sciences Ltd.
$25B 60.0% YTD
Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.